DrugPatentWatch Database Preview
ACTEMRA Drug Profile
» See Plans and Pricing
Summary for Tradename: ACTEMRA
| Patents: | 79 |
| Applicants: | 1 |
| BLAs: | 2 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for ACTEMRA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ACTEMRA |
Recent Clinical Trials for ACTEMRA
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| University of Zurich | Phase 2 |
| Beni-Suef University | Phase 4 |
| October 6 University | Phase 4 |
Recent Litigation for ACTEMRA
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Celgene Corporation v. Aurobindo Pharma Limited | 2018-07-06 |
| AMGEN INC. v. EMCURE PHARMACEUTICALS LTD. | 2018-06-28 |
| AMGEN INC v. SANDOZ INC. | 2018-06-26 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Crescendo Bioscience, Inc | 2017-04-12 |
Pharmacology for ACTEMRA
| Mechanism of Action | Interleukin 6 Receptor Antagonists |
Patent Text Search: US Patents for ACTEMRA
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Get Started for $10 | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Get Started for $10 | OXFORD UNIVERSITY INNOVATION LIMITED (Oxford, GB) | 2034-01-13 | RX | Orphan | search |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Get Started for $10 | 2039-02-26 | RX | Orphan | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Get Started for $10 | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | Orphan | search |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Get Started for $10 | F. HOFFMANN-LA ROCHE INC. (Nutley, NJ) | 2033-07-04 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for ACTEMRA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2011120134 | Get Started for $10 |
| Mexico | 2017010721 | Get Started for $10 |
| South Korea | 20180101626 | Get Started for $10 |
| Singapore | 11201704160X | Get Started for $10 |
| China | 102123739 | Get Started for $10 |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ACTEMRA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| LUC00149 | Luxembourg | Get Started for $10 | PRODUCT NAME: UPADACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
| 2020C/505 | Belgium | Get Started for $10 | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
| 132020000000022 | Italy | Get Started for $10 | PRODUCT NAME: UPADACITINIB IN QUALSIASI FORMA PROTETTA DAL BREVETTO DI BASE(RINVOQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1404, 20191218 |
| 301035 | Netherlands | Get Started for $10 | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1404 20191218 |
| PA2020505 | Lithuania | Get Started for $10 | PRODUCT NAME: UPADACITINIBAS; REGISTRATION NO/DATE: EU/1/19/1404 20191216 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
